Tenax Therapeutics Faces Securities Class Action Lawsuit
A New York law firm has filed a class action against Tenax Therapeutics over alleged investor losses spanning nearly three years of stock trading.
A securities class action lawsuit has been filed against Tenax Therapeutics, Inc. (NASDAQ: TENX), with investors who purchased shares between November 13, 2023, and August 7, 2026, potentially eligible to recover losses, according to an announcement from Bronstein Gewirtz & Grossman, LLC.
The New York-based law firm is urging affected shareholders to come forward ahead of a lead plaintiff deadline of December 28, 2026. Investors who sustained losses during the specified class period are encouraged to contact the firm to discuss their legal options and potential eligibility to participate in the litigation.
Read more Settle Locks In Up to $100M Credit Facility From 3Jane →
Class action lawsuits of this type typically allege that a company or its executives made materially false or misleading statements that artificially inflated the stock price, causing investors to suffer financial harm when the truth was later disclosed. The complaint seeks to recover damages on behalf of qualifying shareholders.
Tenax Therapeutics is a clinical-stage biopharmaceutical company listed on the Nasdaq exchange. Securities class actions involving smaller biotech and pharmaceutical firms are not uncommon, particularly following significant share price declines tied to clinical or regulatory developments.
Shareholders who believe they may qualify as lead plaintiff have until the December 28, 2026 deadline to petition the court. The lead plaintiff represents the broader class of investors throughout the litigation process. Continue reading at All Financial Services & Investing.
